Chen Ruiwan, Wang Chengtao, Zhou Yu, Wen Bixiu
Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China,
Department of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
Cancer Manag Res. 2018 Jul 20;10:2183-2192. doi: 10.2147/CMAR.S162168. eCollection 2018.
To evaluate the prognostic value of circulating Epstein-Barr virus DNA for extra-nodal natural killer/T-Cell lymphoma, nasal type (ENKTL), we performed a meta-analysis of published studies that provided survival information with pre-/post-treatment circulating EBV DNA.
Eligible studies that discussed prognostic significance of circulating EBV DNA in ENKTL were included. Random effects models were applied to obtain the estimated hazard ratios and 95% confidence intervals to evaluate prognostic significance (OS and DFS/PFS). Eleven studies covering a total of 562 subjects were included in this analysis.
The summary HRs and 95% CIs of pre-treatment EBV DNA for OS and PFS/DFS were 4.43 (95% CI 2.66-7.39, <0.00001) and 3.12 (95% CI 1.42-6.85, =0.005), respectively. The corresponding HRs and 95% CIs of post-treatment EBV DNA for OS and PFS/DFS were 6.28 (95% CI 2.75-14.35, <0.0001) and 6.57 (95% CI 2.14-20.16, =0.001). Subgroup analyses indicated a strong trend of prognostic powers with pre-/post-treatment EBV DNA.
With the present evidence, circulating EBV DNA consistently correlated with poorer prognosis in patients with ENKTL which need further investigation in large-scale clinical studies.
为评估循环Epstein-Barr病毒DNA对鼻型结外自然杀伤/T细胞淋巴瘤（ENKTL）的预后价值，我们对已发表的提供治疗前/后循环EBV DNA生存信息的研究进行了荟萃分析。
纳入讨论循环EBV DNA在ENKTL中预后意义的合格研究。应用随机效应模型获得估计的风险比和95%置信区间，以评估预后意义（总生存期和无病生存期/进展期无病生存期）。本分析纳入了11项研究，共562名受试者。
治疗前EBV DNA对总生存期和无进展生存期/无病生存期的汇总风险比及95%置信区间分别为4.43（95%置信区间2.66 - 7.39，<0.00001）和3.12（95%置信区间1.42 - 6.85，=0.005）。治疗后EBV DNA对总生存期和无进展生存期/无病生存期的相应风险比及95%置信区间分别为6.28（95%置信区间2.75 - 14.35，<0.0001）和6.57（95%置信区间2.14 - 20.16，=0.001）。亚组分析表明，治疗前/后EBV DNA具有很强的预后预测趋势。
基于现有证据，循环EBV DNA与ENKTL患者较差的预后始终相关，这需要在大规模临床研究中进一步研究。
